2026 CPTAC Scientific Symposium

Meeting Overview

On September 21, 2026, the National Cancer Institute hosted the Clinical Proteomic Tumor Analysis Consortium (CPTAC) Meeting, bringing together clinical investigators, oncologists, and proteogenomic researchers to share recent findings and explore the integration of proteome-based metrology into clinical trial workflows and Molecular Tumor Boards (MTBs). The meeting highlighted how translating insights from tumor characterization into clinical applications allows proteomics to fill critical gaps left by genomics alone, ultimately improving cancer diagnosis and treatment.

Meeting Highlights

The meeting showcased how proteomics-based technologies are advancing precision oncology, from clinical implementation to large-scale tumor characterization.

• Demonstrated the feasibility of integrating targeted proteomic panels into clinical molecular tumor boards, identifying actionable therapeutic targets that were invisible to standard DNA sequencing alone.
• Combined multiple patient cohorts to reveal population-specific biological differences in disease subtypes and treatment response, pointing toward more precise and equitable approaches to therapy selection.
• Presented multiplexed proteomic assays as objective, standardized alternatives to traditional pathology-based scoring methods, with potential to improve consistency in clinical trial evaluation.
• Showcased how longitudinal molecular monitoring in biofluids can track disease progression in ways that closely matched traditional imaging-based assessments, offering a less invasive complement to existing surveillance methods.
• Unveiled large-scale, multi-layered characterization studies across several cancer types, generating comprehensive atlases that revealed new prognostic subgroups and expanded the foundation for future precision medicine approaches.